ImmunoGen, Inc. Announces Conference Call to Discuss its Second Quarter Fiscal Year 2006 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 26, 2006--ImmunoGen, Inc. (Nasdaq:IMGN) will host a conference call at 4:30 p.m. ET on Thursday, February 2, 2006 to discuss the Company's financial results for the quarter ended December 31, 2005 - the second quarter of ImmunoGen's 2006 fiscal year. Management also will provide an update on the Company.
The call may be accessed live by dialing (913) 981-4900. No passcode is required. Playback of the call will be available from 7:30 p.m. on February 2, 2006 through 11:59 p.m. on February 8, 2006. To listen to the playback, please call (719) 457-0820 and provide passcode 5230482.
Additionally, the call can be heard through the Investor Relations section of ImmunoGen's website, http://www.immunogen.com. Please connect to this website at least 10 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. Following the live webcast, an archived version of the call will be available on the same website through February 8, 2006.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer biopharmaceuticals. The Company's proprietary Tumor-Activated Prodrug (TAP) technology uses tumor-targeting antibodies to deliver a potent, cell-killing agent specifically to cancer cells. Four TAP compounds are in clinical testing - huN901-DM1 and huC242-DM4, which are wholly owned by ImmunoGen, and MLN2704 and AVE9633, which are in development by Millennium Pharmaceuticals, Inc. and the sanofi-aventis Group, respectively. Genentech, Centocor (a wholly-owned subsidiary of Johnson & Johnson), Biogen Idec, the sanofi-aventis Group, Millennium Pharmaceuticals, Inc., Boehringer Ingelheim, and Abgenix have licensed the right to develop and/or test TAP compounds to specific targets; ImmunoGen also has a broader collaboration with the sanofi-aventis Group.
CONTACT: ImmunoGen, Inc.
Carol Hausner, 617-995-2500
info@immunogen.com
SOURCE: ImmunoGen, Inc.
